Placebo for Enlicitide

Phase 3Peptide

Merck & Co.

Placebo for Enlicitide is one of 38 therapeutic programs targeting Hyperlipidemia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

HyperlipidemiaRecruiting

Lipoprotein(a)Recruiting

HyperlipidemiaPhase 3

Recruiting

Lipoprotein(a)Phase 2

Recruiting

Competition

Competitive Landscape

97 competitors in Hyperlipidemia

#DrugCompanyPhaseTrials

Repatha

Amgen

Phase 3

3 2

Avapro

Sanofi

Phase 3

2 3

Lorelco

Sanofi

Phase 3

1 4

Praluent

Regeneron

Phase 3

1 5

Micardis

Boehringer Ingelheim

Phase 3

3 6

Lesinurad

EEsperion Therapeutics, Inc.

Phase 3

2 7

Reyataz

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

1 8

Zocor

OOrganon and Co

Phase 3

1 9

Tricor

JJagotec

Phase 3

1 10

Isentress

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 3Active, not recruiting

Hyperlipidemia

NCT07216482

Q4 2027

Phase 2Recruiting

Lipoprotein(a)

NCT07614984

Clinical

Trials by Indication[1]

Lipoprotein(a)1 trial

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-7262 as Monotherapy and When Coadministered With Enlicitide Decanoate in Adults With Elevated Lipoprotein(a)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT07614984·750 enrolled

Hyperlipidemia1 trial

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Enlicitide Decanoate Coadministered With Rosuvastatin in Adults With Hyperlipidemia

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT07216482·975 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Placebo for Enlicitide. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Placebo for Enlicitide. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Peptide
Highest Phase: Phase 3[1]
Company: Merck & Co.

Placebo for Enlicitide

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q4 2027

Trials by Indication[1]

Lipoprotein(a)1 trial

Hyperlipidemia1 trial

References

Drug Info

Quick Facts

Related News